EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Survival Outcomes Following Yttrium-90 and Holmium-166 Transarterial Radioembolization for Hepatocellular Carcinoma

Dávid Ádám Korda iD, Dénes Balázs Horváthy iD, Sándor Czibor, Domonkos Nádasdy-Horváth, Petra Sólymos iD, Oszkár Háhn, Bálint Tegze, Klára Werling, Attila Jakó, Szabolcs Takács, Pál Ákos Deák iD, András Bibok iD

Cancers · 24.06.2026 · 18 (13) · 2039

DOI: 10.3390/cancers18132039 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 24.06.2026. Verfasst von Dávid Ádám Korda und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Radiology, Heart and Vascular Centre, Semmelweis University, Határőr út 18, H-1122 Budapest, Hungary. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Transarterial radioembolization (TARE) plays an increasing role in the treatment of hepatocellular carcinoma (HCC). Several isotope platforms have been introduced; however, comparative data remain limited. We aimed to compare outcomes following Holmium-166 (Ho-166) and Yttrium-90 (Y-90) TARE in HCC patients.

Methods

We retrospectively analyzed a prospectively maintained cohort of HCC patients treated with Ho-166 or Y-90 TARE between 2022 and 2024. Tumor burden and treatment response were assessed using contrast-enhanced CT or MRI. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan–Meier method and further evaluated using multivariable Cox regression analyses adjusted for baseline confounders.

Results

A total of 73 patients were analyzed, including 39 treated with Y-90 and 34 with Ho-166 TARE. Median follow-up duration was 20.9 months. No significant differences in OS or PFS were observed between treatment groups. Response outcomes, including objective response rate, complete response rate, and duration of response, were also comparable between groups. In the overall cohort, median OS was not reached in Barcelona Clinic Liver Cancer (BCLC) A or B patients and was 12.9 months in BCLC C patients. Median PFS was 20.1, 11.7, and 6.1 months in BCLC A, B, and C patients, respectively.

Conclusions

Ho-166 and Y-90 TARE achieved favorable outcomes across different BCLC stages without significant differences in survival, treatment response, or duration of response between the two platforms. These findings further support the role of TARE in the management of patients with HCC.

Schlagwörter

Stichwörter der Autor:innen

Holmium-166Yttrium-90hepatocellular carcinomaoverall survivalprogression-free survivaltransarterial radioembolization

Autor:innen und Institutionen

  • Department of Interventional Radiology, Heart and Vascular Centre, Semmelweis University, Határőr út 18, H-1122 Budapest, Hungary.
  • Department of Nuclear Medicine, Medical Imaging Centre, Semmelweis University, Korányi Sándor utca 2, H-1083 Budapest, Hungary.
  • Department of Radiology, Medical Imaging Centre, Semmelweis University, Korányi Sándor utca 2, H-1083 Budapest, Hungary.
  • Department of Surgery, Transplantation and Gastroenterology, Semmelweis University, Üllői út 78, H-1082 Budapest, Hungary.
  • Department of Internal Medicine and Haematology, Semmelweis University, Szentkirályi u. 46, H-1088 Budapest, Hungary.
  • Faculty of Humanities, Károli Gáspár University of the Reformed Church in Hungary, Kálvin tér 9, H-1091 Budapest, Hungary.

ORCID-Profile: Dávid Ádám Korda, Dénes Balázs Horváthy, Petra Sólymos, Pál Ákos Deák, András Bibok

Zitieren

APA

Korda, D. Á., Horváthy, D. B., Czibor, S., Nádasdy-Horváth, D., Sólymos, P., Háhn, O., Tegze, B., Werling, K., Jakó, A., Takács, S., Deák, P. Á., & Bibok, A. (2026). Survival Outcomes Following Yttrium-90 and Holmium-166 Transarterial Radioembolization for Hepatocellular Carcinoma. Cancers, 18(13), 2039. https://doi.org/10.3390/cancers18132039

Vancouver

Korda DÁ, Horváthy DB, Czibor S, Nádasdy-Horváth D, Sólymos P, Háhn O, et al. Survival Outcomes Following Yttrium-90 and Holmium-166 Transarterial Radioembolization for Hepatocellular Carcinoma. Cancers. 2026;18(13):2039. doi:10.3390/cancers18132039

BibTeX
@article{Korda2026,
  author = {Korda, Dávid Ádám and Horváthy, Dénes Balázs and Czibor, Sándor and Nádasdy-Horváth, Domonkos and Sólymos, Petra and Háhn, Oszkár and Tegze, Bálint and Werling, Klára and Jakó, Attila and Takács, Szabolcs and Deák, Pál Ákos and Bibok, András},
  title = {Survival Outcomes Following Yttrium-90 and Holmium-166 Transarterial Radioembolization for Hepatocellular Carcinoma},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {13},
  pages = {2039},
  doi = {10.3390/cancers18132039}
}
Kostenlos starten →